L. H. Sehn Et Al. , "Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study," 60th Annual Meeting of the American-Society-of-Hematology (ASH) , vol.132, California, United States Of America, 2018
Sehn, L. H. Et Al. 2018. Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study. 60th Annual Meeting of the American-Society-of-Hematology (ASH) , (California, United States Of America).
Sehn, L. H., Herrera, A. F., Matasar, M. J., Kamdar, M., Assouline, S., Hertzberg, M., ... Kim, T. M.(2018). Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study . 60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America
Sehn, Laurie Et Al. "Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study," 60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 2018
Sehn, Laurie H. Et Al. "Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study." 60th Annual Meeting of the American-Society-of-Hematology (ASH) , California, United States Of America, 2018
Sehn, L. H. Et Al. (2018) . "Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study." 60th Annual Meeting of the American-Society-of-Hematology (ASH) , California, United States Of America.
@conferencepaper{conferencepaper, author={Laurie H. Sehn Et Al. }, title={Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study}, congress name={60th Annual Meeting of the American-Society-of-Hematology (ASH)}, city={California}, country={United States Of America}, year={2018}}